Parent Drug Name | Name of Impurity | Catalogue No. | |
---|---|---|---|
Tenofovir | Tenofovir (MOC-POC-PMPA) | VL470019 | View CAS 1246812-43-0 |
Tenofovir | Tenofovir (S)-Enantiomer | VL470009 | View CAS 1432630-26-6 |
Tenofovir | Tenofovir 9-Allyl Impurity | VE006716 | View CAS 4121-39-5 |
Tenofovir | Tenofovir Adenine impurity / Adenosine EP Impurity A | VL470025 | View CAS 73-24-5 |
Tenofovir | Tenofovir Alafenamide Fumarate | VE009339 | View CAS 379270-38-9 |
Tenofovir | Tenofovir Diethyl Ester (S)-Isomer | VL470012 | View CAS 1217630-57-3 |
Tenofovir | Tenofovir Dimer | VE008551 | View CAS 1607007-18-0 |
Tenofovir | Tenofovir Disoproxil Desmethyl | VL470034 | View CAS 365417-53-4 |
Tenofovir | Tenofovir Disoproxil Dimer Impurity | VL470015 | View CAS 1093279-76-5 |
Tenofovir | Tenofovir Disoproxil Fumarate | VE006981 | View CAS 202138-50-9 |
Tenofovir | Tenofovir Disoproxil Fumarate IP Impurity A | VL470024 | View CAS 211364-69-1 |
Tenofovir | Tenofovir Disoproxil Fumarate IP Impurity D | VL470022 | View CAS 1422284-15-8 |
Tenofovir | Tenofovir Disoproxil Fumarate IP Impurity E | VL470002 | View CAS 1244022-56-7 |
Tenofovir | Tenofovir Disoproxil Fumarate IP Impurity G (Free Base) | VE008089 | View CAS 1280130-08-6 |
Tenofovir | Tenofovir Disoproxil Fumarate IP Impurity M | VL470018 | View CAS 1422284-16-9 |
Tenofovir | Tenofovir Disoproxil Fumarate Impurity (N6-CH2OH-POC PMPA) | VE0014019 | View CAS 1244022-55-6 |
Tenofovir | Tenofovir Disoproxil Isopropoxycarbonyl Impurity | VE008090 | View CAS 1244022-54-5 |
Tenofovir | Tenofovir Disoproxil Related Compound B | VL470021 | View CAS 4121-40-8 |
Tenofovir | Tenofovir IPR Impurity | VL470003 | View CAS 1246812-40-7 |
Tenofovir | Tenofovir Isopropyl Impurity | VL470031 | View CAS 1346597-36-1 |
Tenofovir | Tenofovir ME Impurity | VL470004 | View |
Tenofovir | Tenofovir Mixed Dimer | VL470001 | View CAS 1093279-77-6 |
Tenofovir | Tenofovir Mono POC Dimer | VL470014 | View CAS 1962114-92-6 |
Tenofovir | Tenofovir Monoester | VL470026 | View |
Tenofovir | Tenofovir Monoethyl Ester | VL470011 | View CAS 1796545-19-1 |
Tenofovir | Tenofovir Monoisoproxil Ethoxy Impurity | VE008091 | View CAS 1796539-92-8 |
Tenofovir | Tenofovir NPOC POC PMPA | VL470008 | View CAS 1217542-13-6 |
Tenofovir | Tenofovir Phenyl PMPA | VE008097 | View CAS 379270-35-6 |
Tenofovir | Tenofovir Related Compound 4 | VE008096 | View CAS 851456-00-3 |
Tenofovir | 6N-Hydroxymethyl Tenofovir Disoproxil | VE0014020 | View CAS 1244022-53-4 |
Tenofovir | (R)-9-[2-(Diethylphosphonomethoxy)propyl] Adenine | VE0010429 | View CAS 180587-75-1 |
Tenofovir Related Compound
The virus that causes acquired immunodeficiency syndrome is HIV (AIDS).
References
- Wassner, Chanie, et al. “A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide.” Journal of the International Association of Providers of AIDS Care (JIAPAC), vol. 19, Jan. 2020, p. 232595822091923, https://doi.org/10.1177/2325958220919231. Accessed 7 Mar. 2023.
- “UpToDate.” Uptodate.com, 2023, www.uptodate.com/contents/tenofovir-and-adefovir-for-the-treatment-of-chronic-hbv-infection#:~:text=Tenofovir%20disoproxil%20fumarate%2C%20tenofovir%20alafenamide,because%20it%20is%20more%20potent. Accessed 7 Mar. 2023.
- Lyseng-Williamson, Katherine A., et al. “Tenofovir Disoproxil Fumarate.” Drugs, vol. 65, no. 3, 2005, pp. 413–32, https://doi.org/10.2165/00003495-200565030-00006. Accessed 7 Mar. 2023.
FAQ
What is the therapeutic effect of tenofovir?
Tenofovir-diphosphate inhibits HIV replication by competing for incorporation into DNA during HIV transcription with the natural substrate deoxyadenosine 5′-triphosphate. Tenofovir-diphosphate prevents HBV replication by blocking HBV polymerase.
Can tenofovir be used to treat hepatitis B?
Tenofovir disoproxil fumarate, tenofovir alafenamide, and adefovir are nucleotide reverse transcriptase inhibitors (NRTIs) used to treat chronic HBV infection. Tenofovir, on the other hand, has mostly replaced adefovir because it is more powerful.
Do NRTIs include tenofovir?
Tenofovir, an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is used to treat HIV infection in combination with other antiretroviral drugs.